Area of leased property (sqft) Area of Real Estate Property Commercial and corporate obligations Commercial And Corporate Obligations [Member] Commercial And Corporate Obligations [Member] Aggregate intrinsic value, options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Other (expense) income, net Other Nonoperating Income (Expense) Issued and Outstanding: Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities City Area Code City Area Code Annual increase in number of shares available for issuance Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding Available-for-sale securities, debt securities Total Fair Value Debt Securities, Available-for-sale Equity Components [Axis] Equity Components [Axis] Title of 12(b) Security Title of 12(b) Security Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Minimum Minimum [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Final payment fee Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid Operating lease liabilities, Other current liabilities Operating Lease, Liability, Current Payments on notes payable Repayments of Notes Payable Accrued research, development and manufacturing expenses Accrued Research And Development Expenses, Current Accrued Research And Development Expenses, Current Statistical Measurement [Domain] Statistical Measurement [Domain] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Summary of Weighted Average Assumptions in Stock Option Valuations Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Number of loan installments (in installments) Debt Instrument, Number Of Loan Installments Debt Instrument, Number Of Loan Installments Exercises (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Current Fiscal Year End Date Current Fiscal Year End Date Fair Value Measurements and Available for Sale Investments Fair Value Disclosures [Text Block] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Summary of Activity Related to Stock Option Awards Share-based Payment Arrangement, Option, Activity [Table Text Block] Loss from operations Operating Income (Loss) Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Total current liabilities Liabilities, Current Subsequent Event Type [Domain] Subsequent Event Type [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Accrued professional fees Accrued Professional Fees, Current TESARO TESARO, Inc. And TESARO Development, Inc. [Member] TESARO, Inc. And TESARO Development, Inc. [Member] Long-term investments Debt Securities, Available-for-sale, Noncurrent ASSETS Assets [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Award vesting period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Accounting Policies [Abstract] Accounting Policies [Abstract] Weighted-Average Exercise Price per Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Number of reportable segments Number of Reportable Segments Entity Shell Company Entity Shell Company Cover [Abstract] Cover [Abstract] Cash paid for amounts included in the measurement of lease liabilities Operating Lease, Payments Accounts payable Accounts Payable, Current Document Type Document Type Research and development Research and Development Expense [Member] Schedule of Common Stock Reserved for Future Issuance Schedule Of Common Stock Reserved For Future Issuance [Table Text Block] Schedule Of Common Stock Reserved For Future Issuance [Table Text Block] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Accumulated deficit Retained Earnings (Accumulated Deficit) Operating ROU assets, Other long-term assets Operating Lease, Right-of-Use Asset Total minimum payments required Lessee, Operating Lease, Liability, to be Paid Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Royalty percent on net sales Net Sales Royalty, Percent Net Sales Royalty, Percent 2021 Lessee, Operating Lease, Liability, to be Paid, Year One Celgene Corporation Celgene Corporation [Member] Celgene Corporation [Member] Stock options issued and outstanding (in shares) Stock options outstanding, beginning balance (in shares) Stock options outstanding, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 2024 Lessee, Operating Lease, Liability, to be Paid, Year Four Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Schedule of Assets and Liabilities that Require Fair Value Measurements on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Term B and Term C Loans Term B Loans And Term C Loans [Member] Term B Loans And Term C Loans [Member] IND clearance from the FDA Clearance Of Investigational New Drug From FDA [Member] Clearance Of Investigational New Drug From FDA [Member] Monthly base rate (usd per sqft) Rent Per Square Foot Rent Per Square Foot Classification on the Balance Sheet Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Stockholders' Equity, Beginning Balance (in shares) Stockholders' Equity, Ending Balance (in shares) Shares, Outstanding Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at September 30, 2020 and December 31, 2019, respectively Preferred Stock, Value, Issued Percent of net sales above $1 billion Revenue Recognized, Milestone Method, Milestone Payment Earned, Net Sales above $1 Billion, Percent Revenue Recognized, Milestone Method, Milestone Payment Earned, Net Sales above $1 Billion, Percent Investments outstanding, maturity date range (in years) Available-for-sale Debt Securities, Remaining Maturity Available-for-sale Debt Securities, Remaining Maturity Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Total operating expenses Operating Expenses Document Quarterly Report Document Quarterly Report Stock options exercisable, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Maximum milestone payments per target Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Title of Individual [Axis] Title of Individual [Axis] 12 Months or Greater, Gross Unrealized Losses Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Other long-term liabilities Other Liabilities, Noncurrent Forfeitures and cancellations (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Loan and Security Agreement (LSA) Loan And Security Agreement [Member] Loan And Security Agreement [Member] Other income (expense), net: Nonoperating Income (Expense) [Abstract] Aggregate borrowing capacity Debt Instrument, Face Amount Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Forfeitures and cancellations (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Collaboration revenue Collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax Measurement Frequency [Domain] Measurement Frequency [Domain] General and administrative General and Administrative Expense [Member] Equity [Abstract] Equity [Abstract] Milestone payments, contingent upon achievement of specified levels of worldwide sales (up to) Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Investments at fair value Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure Non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Emerging Growth Company Entity Emerging Growth Company Subsequent Event [Line Items] Subsequent Event [Line Items] Award expiration period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Statement [Line Items] Statement [Line Items] Anti-TIM-3 (GSK4069889A/Cobolimab) AnaptysBio Generated Anti-TIM3 Antagonist Antibody (TSR-022) [Member] AnaptysBio Generated Anti-TIM3 Antagonist Antibody (TSR-022) [Member] Mutual funds Mutual Fund [Member] Schedule of Outstanding Potentially Dilutive Securities Excluded in the Calculation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Forecast Forecast [Member] Net loss per common share: Earnings Per Share, Basic and Diluted [Abstract] Accretion/amortization of investments, net Unrealized Gain (Loss) on Investments Expected term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Document Fiscal Period Focus Document Fiscal Period Focus Debt Disclosure [Abstract] Debt Disclosure [Abstract] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Statement [Table] Statement [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Four Lessee, Operating Lease, Liability, to be Paid, after Year Four Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Agency securities US Government Agencies Debt Securities [Member] Lease termination term Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period Counterparty Name [Axis] Counterparty Name [Axis] Weighted-average number of shares outstanding: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Common stock, $0.001 par value, 500,000 shares authorized, 27,346 shares and 27,255 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively Common Stock, Value, Issued Basic and diluted (in dollars per share) Earnings Per Share, Basic and Diluted Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Receivable Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Receivable Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Receivable Basis of Consolidation Consolidation, Policy [Policy Text Block] Filing of the first MAA - first indication Filing of MMA [Member] Filing of MMA [Member] Filing of the first NDA - first indication Filing of NDA [Member] Filing of NDA [Member] Revenue Recognition [Abstract] Revenue Recognition [Abstract] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Aggregate intrinsic value, options exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Notes Payable Debt Disclosure [Text Block] Milestone payments, contingent upon preclinical and clinical trial events (up to) Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events Weighted average remaining contractual term, options exercisable (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Collaborative Research And Development Agreement Collaborative Arrangement [Member] Sales and maturities of investments Proceeds from Sale and Maturity of Debt Securities, Available-for-sale Subsequent Event [Table] Subsequent Event [Table] Acquisition of investments Payments to Acquire Debt Securities, Available-for-sale Net Loss Per Common Share Earnings Per Share, Policy [Policy Text Block] Prepaid rent Prepaid Rent Increase in annual rent Annual Rent Increase, Percent Annual Rent Increase, Percent Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Stock-based compensation Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Collaborative Research and Development Agreements Collaborative Arrangement Disclosure [Text Block] CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Amendment Flag Amendment Flag Shares reserved for future award grants (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Other Other Accrued Liabilities, Current Balance Sheet Accounts and Supplemental Disclosures Supplemental Balance Sheet Disclosures [Text Block] 2017 Equity Incentive Plan Equity Incentive Plan, 2017 [Member] Equity Incentive Plan, 2017 [Member] Total Operating Lease, Liability Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Measurement Frequency [Axis] Measurement Frequency [Axis] Short-term investments Debt Securities, Available-for-sale, Current Debt Instrument [Line Items] Debt Instrument [Line Items] Capital shares reserved for future issuance, increase (in shares) Common Stock, Capital Shares Reserved For Future Issuance, Increase Common Stock, Capital Shares Reserved For Future Issuance, Increase Financial Instruments [Domain] Financial Instruments [Domain] Total stockholders’ equity Stockholders' Equity, Beginning Balance Stockholders' Equity, Ending Balance Stockholders' Equity Attributable to Parent Amendment Collaboration and Exclusive License Agreement [Member] Collaboration and Exclusive License Agreement Fair Value of Other Financial Instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Description of the Business Nature of Operations [Text Block] Lease Arrangement [Domain] Lease Arrangement [Domain] [Domain] for Lease Arrangement [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Anti-LAG-3 (GSK40974386) AnaptysBio Generated Anti-LAG3 Antagonist Antibody (TSR-033) [Member] AnaptysBio Generated Anti-LAG3 Antagonist Antibody (TSR-033) [Member] Number of outstanding research and development targets Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets 12 Months or Greater, Fair Value Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer Total liabilities and stockholders’ equity Liabilities and Equity Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Amounts accrued for property and equipment Capital Expenditures Incurred but Not yet Paid Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Accrued compensation and related expenses Employee-related Liabilities, Current Subsequent Events Subsequent Events [Text Block] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Local Phone Number Local Phone Number Operating lease cost Operating Lease, Cost General and administrative General and Administrative Expense Financial Instrument [Axis] Financial Instrument [Axis] Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement [Line Items] Dilutive securities excluded from computation of net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Non-cash interest expense Other Noncash Income (Expense) Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Employee stock Employee Stock [Member] Number of one year renewal options Lessee, Operating Lease, One Year Renewal Options, Number Lessee, Operating Lease, One Year Renewal Options, Number Equity Component [Domain] Equity Component [Domain] 2017 Employee Stock Purchase Plan Employee Stock Purchase Plan, 2017 [Member] Employee Stock Purchase Plan, 2017 [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Stock-based compensation APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition Entity Address, Address Line One Entity Address, Address Line One Anti-PD-1 (CC-90006) AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member] AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member] Entity Address, Address Line Two Entity Address, Address Line Two 2022 Lessee, Operating Lease, Liability, to be Paid, Year Two CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Property and equipment, net Total property and equipment, net Property, Plant and Equipment, Net Available-for-sale Investments Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Interest income Interest Income (Expense), Nonoperating, Net Equity Incentive Plans Share-based Payment Arrangement [Text Block] Net loss Net loss Net Income (Loss) Attributable to Parent Entity Address, State or Province Entity Address, State or Province Costs Included in Cash Flow Statement Lease, Cost [Table Text Block] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Other current liabilities Other Liabilities, Current Entity Current Reporting Status Entity Current Reporting Status 2023 Lessee, Operating Lease, Liability, to be Paid, Year Three 2020 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Other long-term assets Other Assets, Noncurrent Plan Name [Axis] Plan Name [Axis] Comprehensive income (loss), net Other Comprehensive Income (Loss), Net of Tax One office lease One Office Lease [Member] One Office Lease [Member] Non-cancellable office leases Lessee, Operating Lease, Number Lessee, Operating Lease, Number Total assets Assets Laboratory equipment Laboratory Equipment [Member] Laboratory Equipment [Member] Scenario [Axis] Scenario [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Total current assets Assets, Current Operating expenses: Operating Expenses [Abstract] Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Weighted average grant date fair value per share (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Subsequent Event Type [Axis] Subsequent Event Type [Axis] Unrealized (loss) income on available for sale securities, net of tax of $0, $(25), $0 and $189, respectively OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Antidilutive Securities [Axis] Antidilutive Securities [Axis] Entity Small Business Entity Small Business Unrealized income (loss) on available for sale securities, tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Entity Interactive Data Current Entity Interactive Data Current Shares Subject to Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Interest expense Interest Expense Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Unrecognized compensation cost Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Not Yet Recognized, Stock Options Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Not Yet Recognized, Stock Options Depreciation and amortization Depreciation, Depletion and Amortization Entity Filer Category Entity Filer Category Lease term Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Certificates of deposit Certificates of Deposit [Member] Product and Service [Axis] Product and Service [Axis] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Supplemental Cash Flow Information [Abstract] Aggregate draw on term loan Proceeds from Notes Payable Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Fair Value Debt Securities, Available-for-sale, Unrealized Loss Position Common Stock Common Stock [Member] Product and Service [Domain] Product and Service [Domain] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Phase 1 clinical trial initiation Phase 1 Clinical Trial Initiation [Member] Phase 1 Clinical Trial Initiation [Member] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Quoted Market Prices for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Upfront license fee received Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received Property and Equipment Property, Plant and Equipment [Table Text Block] Milestone payments, contingent upon certain U.S. and European regulatory submissions and approvals (up to) Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Document Fiscal Year Focus Document Fiscal Year Focus Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Less than 12 Months, Fair Value Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months U.S. Treasury securities US Treasury Securities [Member] Leasehold improvements Leasehold Improvements [Member] Debt Instrument [Axis] Debt Instrument [Axis] Additional Paid-in Capital Additional Paid-in Capital [Member] Less than 12 Months, Gross Unrealized Losses Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Fixed interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Money market funds Money Market Funds [Member] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Class of Stock [Line Items] Class of Stock [Line Items] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Shares issued under employee stock plans (in shares) Exercises (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Net increase in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Total other income (expense), net Nonoperating Income (Expense) Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Schedule of Future Minimum Annual Obligations Lessee, Operating Lease, Liability, Maturity [Table Text Block] Options to purchase common stock Share-based Payment Arrangement, Option [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Research and development Research and Development Expense Subsequent Events [Abstract] Subsequent Events [Abstract] Subsequent event Subsequent Event [Member] Milestone Event Revenue Recognized, Milestone Method, Milestone Payment Earned Revenue Recognized, Milestone Method, Milestone Payment Earned Stock options outstanding, beginning balance (in dollars per share) Stock options outstanding, ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Notes Payable to Banks Notes Payable to Banks [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Carrying Amount Reported Value Measurement [Member] Plan Name [Domain] Plan Name [Domain] Property and equipment, gross Property, Plant and Equipment, Gross Proceeds from issuance of common stock, upon the exercise of stock options Proceeds from Stock Options Exercised Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Additional paid-in capital Additional Paid in Capital Document Period End Date Document Period End Date Provision for income taxes Income Tax Expense (Benefit) Milestones achieved, amount Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount Entity Registrant Name Entity Registrant Name Fair Value Estimate of Fair Value Measurement [Member] Income Statement [Abstract] Income Statement [Abstract] Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Operating lease liabilities, Other long-term liabilities Operating Lease, Liability, Noncurrent Title of Individual [Domain] Title of Individual [Domain] Accrued expenses Total accrued expenses Accrued Liabilities, Current Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Use of Estimates Use of Estimates, Policy [Policy Text Block] Current assets: Assets, Current [Abstract] Anti-PD-1 (GSK4057190A/Dostarlimab) Anti-PD-1 AnaptysBio-generated Anti-PD-1 Antagonist Antibody (TSR-042) [Member] AnaptysBio-generated Anti-PD-1 Antagonist Antibody (TSR-042) [Member] 10770 Wateridge Circle, San Diego, California 92121 10770 Wateridge Circle, San Diego, California 92121 [Member] 10770 Wateridge Circle, San Diego, California 92121 Phase 3 clinical trial initiation Phase 3 Clinical Trial Initiation [Member] Phase 3 Clinical Trial Initiation [Member] Shares issued under employee stock plans Stock Issued During Period, Value, Stock Options Exercised Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Agreement term following first commercial sale or expiration of the last to expire patent (in years) Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Number of milestones achieved during period Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period Lease Arrangement [Axis] Lease Arrangement [Axis] Lease Arrangement [Axis] Award Type [Axis] Award Type [Axis] Scenario [Domain] Scenario [Domain] Debt instrument, maximum borrowing capacity Debt Instrument, Maximum Borrowing Capacity Debt Instrument, Maximum Borrowing Capacity Counterparty Name [Domain] Counterparty Name [Domain] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Maximum Maximum [Member] Security Exchange Name Security Exchange Name Phase 2 clinical trial initiation Phase 2 Clinical Trial Initiation [Member] Phase 2 Clinical Trial Initiation [Member] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Entity Tax Identification Number Entity Tax Identification Number Term A Loans Term A Loans [Member] Term A Loans [Member] Accumulated Deficit Retained Earnings [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Measurement Basis [Axis] Measurement Basis [Axis] Gross Unrealized Losses Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss Common stock, shares reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Director Stock options Director [Member] Weighted average remaining contractual term, options outstanding (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Weighted average period remaining for amortization of unrecognized compensation cost (in years) Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not Yet Recognized, Period For Recognition Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not Yet Recognized, Period For Recognition Security deposit Security Deposit Award Type [Domain] Award Type [Domain] Loss before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Trading Symbol Trading Symbol Operating lease, term of contract Lessee, Operating Lease, Term of Contract Document Transition Report Document Transition Report Stock options exercisable, ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Notes payable, current portion Notes Payable, Current Summary of Non-cash Stock-based Compensation Expense Share-based Payment Arrangement, Cost by Plan [Table Text Block] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Notes payable Notes Payable, Fair Value Disclosure Office furniture and equipment Office Equipment [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Current liabilities: Liabilities, Current [Abstract] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Phase 3 clinical trial initiation - second indication [Domain] Phase 3 clinical trial initiation - second indication [Domain] Phase 3 clinical trial initiation - second indication [Domain] Percent of net sales below $1 billion Revenue Recognized, Milestone Method, Milestone Payment Earned, Net Sales below $1 Billion, Percent Revenue Recognized, Milestone Method, Milestone Payment Earned, Net Sales below $1 Billion, Percent Lease renewal term Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term Schedule of Unrealized Loss and Fair Values in a Loss Position Schedule of Unrealized Loss on Investments [Table Text Block] Accounting Pronouncements Recently Adopted New Accounting Pronouncements, Policy [Policy Text Block] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Initiated in vivo toxicology studies using good laboratory practices (GLPs) In Vivo Toxicology Studies [Member] In Vivo Toxicology Studies [Member]